Table 1. Correlation of serum IL-10 level with clinical characteristics in MM patients.
| Characteristics | N=188 | Median concentration, pg ml−1 (range) | P-value |
|---|---|---|---|
| Age | 0.873 | ||
| <65 | 108 | 164.69 (23.08–553.54) | |
| ⩾65 | 80 | 179.91 (13.65–1877.44) | |
| Gender (male) | 132 | 165.66 (13.65–1877.44) | 0.608 |
| ECOG PS | 0.004 | ||
| 0–1 | 104 | 161.19 (18.54–465.78) | |
| ⩾2 | 84 | 187.76 (13.65–1877.44) | |
| ISS stage | 0.028 | ||
| I | 45 | 118.65 (13.65–465.78) | |
| II | 83 | 173.75 (18.54–449.54) | |
| III | 60 | 194.61 (65.45–1877.44) | |
| Type of myeloma | 0.301 | ||
| IgG | 90 | 164.16 (18.54–449.54) | |
| IgA | 58 | 174.29 (13.65–1877.44) | |
| Light chain | 40 | 173.75 (23.08–553.54) | |
| Serum LDH | 0.006 | ||
| ⩽ULN | 143 | 164.84 (13.65–1877.44) | |
| >ULN | 45 | 187.54 (65.45–1877.44) | |
| Genetic abnormalities | 0.072 | ||
| Yesa | 72 | 196.78 (18.54–498.43) | |
| No | 116 | 164.50 (13.65–1877.44) | |
| Treatment regimens | 0.376 | ||
| Bortezomib based | 84 | 162.73 (23.08–498.43) | |
| DVD | 104 | 174.28 (13.65–1877.44) | |
| Treatment response | <0.001 | ||
| CR | 36 | 112.46 (23.08–389.48) | |
| Less than CR | 152 | 174.29 (13.65–1877.44) |
Abbreviations: CR=complete response; DVD=doxil, vincristine, and dexamethasone; ECOG PS=Eastern Cooperative Oncology Group Performance Status; Ig=immunoglobulin; IL-10=interleukin-10; ISS=International Staging System; LDH=lactate dehydrogenase; MM=multiple myeloma; ULN=upper limit of normal.
a
Patients with abnormalities of 13q14, 1q21, 14q32, and 17p13.